Interestingly, local administration of EGFRvIII-targeting CAR-T cells that simultaneously secrete TCEs against wild-type EGFR, achieved radiographic tumor regression in patients with glioblastoma, and demonstrated a safe profile (7). The gene discussed is EGFR; the disease is glioblastoma.